Drug Name: 

NESVACUMAB + AFLIBERCEPT^

Drug Description: 
Ang2 Antibody + Aflibercept
Target Condition: 
Wet age-related macular degeneration, diabetic macular edema
Rank: 
40
Phase: 
Phase 2

NOW APPROVED IN THE UNITED STATES